Combined therapy in leprosy. Background and findings

Area of Science:

• Microbiology
• Infectious Diseases
• Dermatology

Background:

• Leprosy remains a significant global health challenge, particularly lepromatous leprosy.
• Dapsone (DDS) monotherapy has historically been used but often leads to persistent bacterial loads.
• Drug resistance and treatment efficacy necessitate exploring alternative therapeutic strategies.

Purpose of the Study:

• To evaluate the efficacy of combination therapy for lepromatous leprosy.
• To assess bacterial load reduction in patients undergoing multi-drug treatment.
• To determine the long-term impact of combination therapy on bacterial persistence.

Main Methods:

• Analysis of biopsy homogenates from 64 lepromatous leprosy patients.
• Monitoring bacterial counts during and after combination therapy (rifampicin + isoprodian [isoniazid + prothionamide + dapsone]).
• Inclusion of therapy-free observation periods for long-term efficacy assessment.

Main Results:

• Combination therapy demonstrated a significant logarithmic decrease in bacterial numbers.
• Bacterial reduction was observed during treatment and continued in therapy-free periods.
• Rapid regression of bacterial mass and achievement of "negativity" were noted in a short timeframe.

Conclusions:

• Combination therapy, including rifampicin and isoprodian, is highly effective against persistent leprosy bacteria.
• The observed bacterial reduction persists post-therapy, indicating sustained treatment benefits.
• Extended therapy-free observation periods are crucial for accurately evaluating leprosy treatment efficacy.